哈佛生物科学 HBIO 深 沪
交易中 07-01 11:05:42 美东时间
6.07
-0.080
-1.30%
华盛通- 最 高6.15
- 今 开6.15
- 成交量 3139股
- 最 低 6.0499
- 昨 收 6.15
- 总市值 2737.68万
- 52周最高 9.40
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 3.755
- 委 比 1.27%
- 总股本 451.02万
- 历史最高 87.50
- 量 比 1.21
- 振 幅 1.63%
- 历史最低 2.813
- 每 手 1
- 风险率 0.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial officer, effective as of
05-30 04:09
哈佛生物科学重申2026年营收增长2%-4%，“维京计划”剑指年省400万美元
哈佛生物科学公司周二公布第一季度财报，并重申全年业绩指引。尽管一季度营收同比略有下滑，公司仍维持2026全年营收增长2%至4%的预期，同时“维京计划”制造整...
05-13 03:07
Harvard Bioscience shares are trading lower after the company reported mixed Q1 financial results.
Harvard Bioscience shares are trading lower after the company reported mixed Q1...
05-12 23:53
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
05-12 19:34
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of $(0.10) per share from
05-12 19:33
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
03-13 20:48
Harvard Bioscience Sees Q1 Sales $20.000M-$22.000M vs $21.250M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million analyst estimate.
03-12 19:32
